KLOW Stack: GHK-Cu, TB-500, BPC-157 and KPV in a Research Blend

The KLOW Stack is a fixed mixture of four research peptides in a single lyophilized vial: GHK-Cu, TB-500, BPC-157 and KPV. The composition specified for this article is GHK-Cu 25 mg, TB-500 10 mg, BPC-157 10 mg and KPV 10 mg, for a total mass of 55 mg. KLOW is a vendor-coined name, not a standardized formulation, and is intended exclusively for research purposes.

What is the KLOW Stack and why is it a blend?

KLOW does not denote a single active compound but a fixed multi-peptide blend that bundles four different research peptides together in one vial. The name is an acronym of the components it contains and was coined by vendors; there is no pharmacopoeia-compliant or otherwise standardized reference formulation. This has a practical consequence: the KLOW vials sold on the market differ considerably, above all in their GHK-Cu loading and therefore in their total mass.

The variant used as the basis for this article contains GHK-Cu 25 mg, TB-500 10 mg, BPC-157 10 mg and KPV 10 mg, totaling 55 mg. A very common alternative carries GHK-Cu 50 mg with the same loading of the other three components, bringing it to 80 mg total mass. For this reason, always read the mg breakdown stated on the particular vial. The component-specific science we describe below is dose-independent, but the concentration per milliliter after reconstitution depends directly on the exact vial loading.

The blend rationale rests on the fact that the four peptides address largely non-overlapping nodes of tissue regeneration: cell migration and angiogenesis, VEGFR2-mediated vessel formation plus cytoprotection, extracellular matrix remodeling, and inflammation-dampening signal modulation. Vendors argue that a single vial thus covers angiogenesis, matrix and inflammation simultaneously, a concept that is to be understood exclusively as preclinical.

Which four components does the KLOW Stack contain?

KLOW combines four structurally and mechanistically distinct peptides. GHK-Cu (glycyl-L-histidyl-L-lysine complexed with copper(II)) is an endogenous human tripeptide of the sequence Gly-His-Lys that chelates Cu2+; the copper is coordinated via the imidazole nitrogen of the histidine, the alpha-amino group of the glycine and a deprotonated amide nitrogen, which neutralizes copper redox toxicity and enables non-toxic copper transport. At 25 mg, GHK-Cu is the quantitatively dominant component of this variant.

TB-500 is marketed as a synthetic analog of thymosin beta-4; the actual research entity is the N-acetylated active fragment Ac-LKKTETQ (Tbeta4 residues 17 to 23), the actin-binding region whose binding site was mapped by Van Troys et al., 1996. BPC-157 is a stable gastric pentadecapeptide of 15 amino acids with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a partial fragment of the human gastric juice protein BPC.

KPV, finally, is the tripeptide Lys-Pro-Val, the C-terminal fragment (residues 11 to 13) of the alpha-melanocyte-stimulating hormone (alpha-MSH). It is the only component that, despite its alpha-MSH origin, does not act through melanocortin receptors. Each of these four components brings its own molecular point of attack, which the next sections break down individually.

What does GHK-Cu contribute to the KLOW Stack?

In the blend, GHK-Cu supplies the matrix and antioxidant axis. Endogenously, the plasma level of GHK declines with age from about 200 ng/mL at age 20 to roughly 80 ng/mL at age 60 Pickart et al., 2015; Dou et al., 2020. At non-toxic concentrations of 1 to 10 nM, the peptide stimulates in preclinical models both the synthesis and the breakdown of collagen and glycosaminoglycans such as dermatan and chondroitin sulfate as well as decorin, and it modulates matrix metalloproteinases together with their inhibitors TIMP-1 and TIMP-2.

In addition, GHK-Cu induces growth factors such as bFGF and VEGF and acts as a ROS scavenger; in Caco-2 cells, an approximately 50 percent reduction of t-BHP-induced ROS was reported at 10 microM. At the gene level, GHK-Cu modulates a large share of the human transcriptome: an influence on roughly 31.2 percent of genes at a change of at least 50 percent is reported, of which about 59 percent are upregulated and 41 percent downregulated, with upregulation of about 84 DNA repair genes and ubiquitin-proteasome genes as well as suppression of proinflammatory signals such as IL-6 and NF-kB-driven TNF Pickart et al., 2018.

In-vivo references cite for bone healing studies about 140 microg per injection over 10 days; the estimated human therapeutic systemic exposure is around 100 to 200 mg Pickart et al., 2015. GHK-Cu is at the same time the most sensitive peptide of the blend and therefore rate-limiting for stability.

What do TB-500 and BPC-157 contribute?

TB-500 and BPC-157 together form the migration and angiogenesis axis of the blend. The primary molecular target of the TB-500 fragment is monomeric G-actin: thymosin beta-4 is the most important intracellular G-actin-sequestering peptide and buffers the equilibrium between G- and F-actin, by which it regulates cytoskeletal dynamics, cell migration, angiogenesis and wound repair. Common research protocols for the heptapeptide fragment range around 2 to 5 mg per week, split across the week, with twice-weekly loading schedules reflecting the multi-day tissue persistence.

BPC-157 adds a receptor-coupled angiogenesis plus cytoprotection. It acts pro-angiogenically via VEGFR2: the peptide promotes VEGFR2 internalization and activates the VEGFR2-Akt-eNOS pathway, which is blocked by the endocytosis inhibitor Dynasore, and in preclinical models it increased vessel density as well as the restoration of blood flow in the ischemic rat hindlimb Hsieh et al., 2017. In muscle and tendon injury models, BPC-157 upregulates VEGF and delivers what the authors call an adequately modulated angiogenesis with improved healing Brcic et al., 2009.

Both peptides thus address complementary aspects of vessel formation: TB-500 via the intracellular actin dynamics of the migrating cells, BPC-157 via the receptor-mediated VEGFR2-NO axis. Reported rodent doses for BPC-157 frequently fall in ranges of 10 microg/kg to 10 ng/kg. The cytoprotection concept after Robert and Szabo is extended systemically via modulation of the NO system Sikiric et al., 2025.

What does KPV contribute to the KLOW Stack?

KPV is the inflammation-dampening component and at the same time the difference between KLOW and the related GLOW blend. Notably, the anti-inflammatory mechanism of KPV is melanocortin-receptor-independent, even though the tripeptide is derived from alpha-MSH. Instead, KPV is taken up via the di- and tripeptide transporter PepT1 in epithelial and immune cells; the intestinal Km value is about 160 microM, in Jurkat T cells about 700 microM. Once inside, the peptide accumulates in the cell nucleus.

There, KPV inhibits the activation of NF-kB by delaying the turnover of NF-kB and IkBalpha, and it additionally suppresses the phosphorylation of MAPK, namely ERK1/2, JNK and p38. At nanomolar concentrations, the tripeptide dampens proinflammatory cytokines: a reduction of IL-8 mRNA by about 35 percent is reported, as well as lower levels of IL-6, IL-12, IFN-gamma and IL-1beta. In murine colitis models, KPV lowered myeloperoxidase by roughly 50 percent in the DSS model and reduced inflammation markers by about 30 percent in the TNBS model; in vivo it was dosed at 100 microM in the drinking water, in vitro at 10 nM to 100 microM Dalmasso et al., 2008.

In the KLOW blend, KPV thus adds its own inflammation axis via NF-kB and MAPK that is not present in this form in the other three components. It is precisely this axis that KLOW adds over GLOW as an additional anti-inflammatory tripeptide.

Why are these four peptides combined?

The blend thesis of the KLOW Stack is that four complementary, largely non-overlapping nodes of tissue regeneration can be bundled in one vial. TB-500 drives cytoskeletal and cell migration as well as angiogenesis via actin dynamics. BPC-157 adds a VEGFR2-mediated angiogenesis plus cytoprotection via the NO axis. GHK-Cu supplies the extracellular matrix remodeling via collagen, glycosaminoglycans and the MMP-TIMP system as well as an antioxidant and growth-factor-inducing component. KPV layers an NF-kB- and MAPK-mediated inflammation dampening on top.

The intended preclinical use case, per vendor argumentation, are composite injury models, chronic inflammation and regeneration models, in which the combination is meant to address angiogenesis, matrix and inflammation simultaneously. Mechanistically, the axes interlock: GHK-Cu and BPC-157 both induce VEGF, so the pro-angiogenic activity of three of the four components converges, while TB-500 supplies the migratory cytoskeletal response of the mobilized cells and KPV dampens the accompanying inflammation.

Important is the sober classification: there are no controlled human data on the KLOW blend as a whole. The component science comes from individual studies on one peptide at a time, not from investigations of the fixed quadruple mixture. Synergy is postulated but is not clinically proven for this specific combination. Anyone who wants to follow the computational split of the components per milliliter can calculate the KLOW Stack in the Peptide Calculator to visualize concentrations based on the respective vial loading.

How is the KLOW Stack reconstituted and dosed?

Since KLOW comes as a fixed blend, the four components cannot be dosed separately; every withdrawn amount contains the fixed ratio. In the specified 55 mg variant, GHK-Cu, TB-500, BPC-157 and KPV are in a ratio of 25 to 10 to 10 to 10. The concentration per milliliter after reconstitution follows directly from the volume of bacteriostatic water added. If, for example, you reconstitute 55 mg total mass with 2.75 mL, each milliliter contains a calculated 20 mg of total peptide, of which about 9.1 mg is GHK-Cu and 3.6 mg each of the other three components.

The research ranges cited in the component science serve for classification, not as a protocol: for the TB-500 fragment, research protocols cite about 2 to 5 mg per week, GHK-Cu in-vivo references are around 140 microg per injection in animal models, and KPV was used in vivo at 100 microM in the drinking water. These numbers come from heterogeneous models and are not interconvertible.

During reconstitution, the stability of the most sensitive component is decisive. GHK-Cu is highly sensitive to carboxypeptidase cleavage, light-driven copper photo-oxidation and pH extremes, with an optimal range of about 5.0 to 6.5. Add the solvent slowly onto the vial wall, swirl rather than shake, and protect the solution from light. All of these are handling notes in a research context and not a dosing recommendation.

How is the KLOW Stack stored and how stable is it?

The stability of the entire blend is determined by the least stable component, and that is clearly GHK-Cu. All of the following values are handling figures in degrees Celsius and not peer-reviewed stability assays.

As a lyophilized powder: freezing at minus 20 degrees Celsius for long-term storage over about 18 to 24 months, refrigeration at 2 to 8 degrees Celsius is acceptable for roughly 12 to 18 months, and room temperature should be used only for about 2 to 4 months. After reconstitution with bacteriostatic water, the solution should be refrigerated at 2 to 8 degrees Celsius and used up within about 28 to 30 days. If preservative-free sterile water is used instead, the usable shelf life shortens to about 24 to 48 hours.

Three factors are especially critical for the KLOW blend because they specifically affect GHK-Cu: protect the copper peptide from light to avoid photo-oxidation, keep the pH in the optimal range of about 5.0 to 6.5 and avoid pH extremes, and minimize freeze-thaw cycles, as these favor aggregation and oxidation. Anyone who aliquots the blend into smaller working amounts reduces repeated thawing of the entire batch. Since GHK-Cu is rate-limiting, these precautions apply to the entire vial, even though the other three peptides are more robust on their own.

What is the half-life of the KLOW Stack?

For the KLOW blend as a unit, no published half-life exists; the pharmacokinetics are component-specific, and only one of the four components has robust human values. The hard numbers come from thymosin beta-4, the parent molecule of TB-500. In a Phase I study with recombinant human thymosin beta-4, the terminal half-life was about 0.5 to 2.08 hours, for example 1.02 hours at 0.5 microg/kg and up to 2.08 hours at 25 microg/kg, with linear, non-accumulating kinetics and dose-proportional Cmax Wang et al., 2021. Single doses of 42, 140, 420 and 1260 mg intravenously were well tolerated and showed dose-proportional, linear pharmacokinetics, with the half-life increasing with the dose Ruff et al., 2010.

It is important that these values apply to the complete thymosin beta-4, not to the TB-500 heptapeptide fragment Ac-LKKTETQ itself, whose human half-life is not formally published; the twice-weekly research dosing, however, implies a multi-day tissue persistence.

For the other three components, validated human values are lacking. GHK-Cu has no clean systemic half-life; it is rapidly cleaved by carboxypeptidases, which suggests a short plasma residence time Pickart et al., 2018. The human pharmacokinetics of BPC-157 are unpublished; in rodents it is described as unusually resistant to degradation Sikiric et al., 2025. For KPV, the effect is driven by PepT1-mediated cellular uptake, not by circulating levels, which is why no formal plasma half-life exists Dalmasso et al., 2008.

How does the KLOW Stack differ from the GLOW blend?

KLOW and GLOW are the same concept, with exactly one difference: KLOW equals GLOW plus KPV. GLOW is typically a mixture of BPC-157, TB-500 and GHK-Cu, for example as a 70 mg blend, and therefore has no dedicated anti-inflammatory NF-kB axis. KLOW adds to this trio the alpha-MSH-derived tripeptide KPV, which contributes inflammation dampening via inhibition of NF-kB and MAPK. So anyone looking for the migration, angiogenesis and matrix axis finds it in both blends; only KLOW explicitly adds the inflammation-modulating component.

Within the KLOW blend, the four peptides differ fundamentally in their mode of action. GHK-Cu is the only component that carries a redox-neutralized copper payload and acts at the gene and ECM level rather than via a single receptor. TB-500 is a fragment analog, not the complete thymosin beta-4, and acts intracellularly on G-actin rather than via a surface receptor. BPC-157 is receptor-coupled via VEGFR2 and the NO system and is considered orally and parenterally stable in rodents. KPV is the only component that, despite its alpha-MSH origin, is not melanocortin-receptor-mediated, which distinguishes it from complete alpha-MSH and melanotan analogs.

This heterogeneity is at once the vendors' argument for the blend and the reason why storage must be aligned to the most sensitive component. All statements are preclinical or early-clinical and not clinical guidance.

What side effects and limitations are known for the KLOW Stack?

For the KLOW blend as a whole, no controlled human safety data exist; it is sold strictly for research purposes only and is not an approved therapeutic. The safety information is therefore to be read component by component and always with reservation. For complete thymosin beta-4, intravenous single doses of up to 1260 mg were well tolerated in healthy subjects, with no dose-limiting toxicity Ruff et al., 2010, and recombinant thymosin beta-4 showed no accumulation Wang et al., 2021.

BPC-157 is described as well tolerated and without demonstrated toxicity in rodents, but the human safety dossier is unpublished, and over 80 percent of the literature comes from a single research group, so independent replication is limited Sikiric et al., 2025. GHK-Cu is non-toxic in vitro at nanomolar to micromolar concentrations; the main reservations are the handling and photo-oxidation of the copper peptide as well as the theoretical copper load with chronic high-dose use. KPV shows a benign profile in rodent colitis but has no human pharmacovigilance.

As a theoretical combination risk, the stacked pro-angiogenic activity of TB-500, BPC-157 and GHK-Cu via VEGF applies; it is precisely this property that critics flag as an unquantified concern, for example in the context of occult neoplasia or proliferative diseases. All figures stated here are preclinical or early-clinical and must not be read as a clinical recommendation.

Frequently asked questions about the KLOW Stack

Is the KLOW Stack the same as GLOW?

No, but they are closely related. KLOW corresponds to the GLOW blend plus the additional tripeptide KPV. GLOW typically combines BPC-157, TB-500 and GHK-Cu, while KLOW contains the same three components plus KPV, which contributes an anti-inflammatory axis via inhibition of NF-kB and MAPK Dalmasso et al., 2008. KLOW thus additionally covers inflammation modulation.

Why does the composition of the KLOW Stack vary between vendors?

Because KLOW is a vendor-coined name without a standardized formulation. The variant in this article contains GHK-Cu 25 mg at 55 mg total mass; another common variant carries GHK-Cu 50 mg at 80 mg total mass. The per-mL concentration after reconstitution depends directly on the respective vial loading, which is why you should always read the stated mg breakdown.

Which component determines the storage of the KLOW Stack?

GHK-Cu, the most sensitive of the four peptides. It is susceptible to carboxypeptidase cleavage, light-driven copper photo-oxidation and pH extremes, with an optimum of about 5.0 to 6.5. Since the blend stability is limited by the weakest component, light protection, pH caution and minimizing freeze-thaw cycles apply to the entire vial.

Is there a human half-life for the KLOW Stack?

Not for the blend as a unit. Only thymosin beta-4, the parent molecule of TB-500, has robust human values with a terminal half-life of about 0.5 to 2.08 hours Wang et al., 2021. GHK-Cu, BPC-157 and KPV have no validated human pharmacokinetics.

Is the KLOW Stack approved for human use?

No. The KLOW Stack is sold strictly for research purposes only and is not an approved therapeutic. There are no controlled human safety data on the fixed quadruple mixture, and all data summarized here come from preclinical or early-clinical individual studies on the components.

For research purposes only. Not intended for human consumption. Scientific editor: Dr. Sieglinde Klaus